Microwave expedited synthesis of 5-aminocamptothecin analogs : Inhibitors of hypoxia inducible factor HIF-1αTORREGROSSA, Joelle; BUBLEY, Glenn J; JONES, Graham B et al.Bioorganic & medicinal chemistry letters (Print). 2006, Vol 16, Num 23, pp 6082-6085, issn 0960-894X, 4 p.Article

Biology of prostate-specific antigenBALK, Steven P; KO, Yoo-Joung; BUBLEY, Glenn J et al.Journal of clinical oncology. 2003, Vol 21, Num 2, pp 383-391, issn 0732-183X, 9 p.Article

Clonal Progression of Prostate Cancers from Gleason Grade 3 to Grade 4SOWALSKY, Adam G; HUIHUI YE; BUBLEY, Glenn J et al.Cancer research (Chicago, Ill.). 2013, Vol 73, Num 3, pp 1050-1055, issn 0008-5472, 6 p.Article

The effect of androgen deprivation therapy on fasting serum lipid and glucose parametersYANNUCCI, Jennifer; MANOLA, Judi; GARNICK, Marc B et al.The Journal of urology. 2006, Vol 176, Num 2, pp 520-525, issn 0022-5347, 6 p.Article

Accuracy of Endorectal Magnetic Resonance/Transrectal Ultrasound Fusion for Detection of Prostate Cancer During BrachytherapyBUBLEY, Glenn J; BLOCH, B. N; VAZQUEZ, Cesar et al.Urology (Ridgewood, NJ). 2013, Vol 81, Num 6, pp 1284-1289, issn 0090-4295, 6 p.Article

Phase II Study of Abiraterone Acetate in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Displaying Bone Flare Discordant with Serologic ResponseRYAN, Charles J; SHAH, Shreya; MOLINA, Arturo et al.Clinical cancer research (Print). 2011, Vol 17, Num 14, pp 4854-4861, issn 1078-0432, 8 p.Article

An image contrast agent selectively activated by prostate specific antigenJONES, Graham B; CRASTO, Curtis F; MATHEWS, Jude E et al.Bioorganic & medicinal chemistry. 2006, Vol 14, Num 2, pp 418-425, issn 0968-0896, 8 p.Article

Image contrast agents activated by prostate specific antigen (PSA)JONES, Graham B; LONGFEI XIE; EL-SHAFEY, Ahmed et al.Bioorganic & medicinal chemistry letters (Print). 2004, Vol 14, Num 12, pp 3081-3084, issn 0960-894X, 4 p.Article

Docetaxel, estramustine, and short-term androgen withdrawal for patients with biochemical failure after definitive local therapy for prostate cancerTAPLIN, Mary-Ellen; BUBLEY, Glenn J; RAJESHKUMAR, Barur et al.Seminars in oncology. 2001, Vol 28, Num 4, pp 32-39, issn 0093-7754, SUP15Article

Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial CancerCHOUEIRI, Toni K; ROSS, Robert W; BUCKLE, Geoffrey C et al.Journal of clinical oncology. 2012, Vol 30, Num 5, pp 507-512, issn 0732-183X, 6 p.Article

Identification of the Transcription Factor Single-Minded Homologue 2 as a Potential Biomarker and Immunotherapy Target in Prostate CancerARREDOUANI, Mohamed S; BIN LU; SANDA, Martin G et al.Clinical cancer research (Print). 2009, Vol 15, Num 18, pp 5794-5802, issn 1078-0432, 9 p.Article

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone : Recommendations of the Prostate Cancer Clinical Trials Working GroupSCHER, Howard I; HALABI, Susan; PETRYLAK, Daniel et al.Journal of clinical oncology. 2008, Vol 26, Num 7, pp 1148-1159, issn 0732-183X, 12 p.Article

Hypoxia-inducible factor-2a : effect on radiation sensitivity and differential regulation by an mTOR inhibitorBHATT, Rupal S; LANDIS, Daniel M; ZIMMER, Michael et al.BJU international (Papier). 2008, Vol 102, Num 3, pp 358-363, issn 1464-4096, 6 p.Article

Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancerSTANBROUGH, Michael; BUBLEY, Glenn J; ROSS, Kenneth et al.Cancer research (Baltimore). 2006, Vol 66, Num 5, pp 2815-2825, issn 0008-5472, 11 p.Article

Is the flare phenomenon clinically significant? CommentaryBUBLEY, Glenn J; GLEAVE, Martin E; TRACHTENBERG, John et al.Urology (Ridgewood, NJ). 2001, Vol 58, Num 2A, pp 5-9, issn 0090-4295Conference Paper

Intratumoral De Novo Steroid Synthesis Activates Androgen Receptor in Castration-Resistant Prostate Cancer and Is Upregulated by Treatment with CYP17A1 InhibitorsCHANGMENG CAI; SEN CHEN; SHAOYONG CHEN et al.Cancer research (Chicago, Ill.). 2011, Vol 71, Num 20, pp 6503-6513, issn 0008-5472, 11 p.Article

Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate CancerDANILA, Daniel C; MORRIS, Michael J; MOLINA, Arturo et al.Journal of clinical oncology. 2010, Vol 28, Num 9, pp 1496-1501, issn 0732-183X, 6 p.Article

A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormonesTAPLIN, Mary-Ellen; MANOLA, Judith; OH, William K et al.BJU international (Papier). 2008, Vol 101, Num 9, pp 1084-1089, issn 1464-4096, 6 p.Article

Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancerOH, William K; KANTOFF, Philip W; DIPAOLA, Robert S et al.Journal of clinical oncology. 2004, Vol 22, Num 18, pp 3705-3712, issn 0732-183X, 8 p.Article

Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancerGEORGE, Daniel J; REGAN, Meredith M; OH, William K et al.Urology (Ridgewood, NJ). 2004, Vol 63, Num 2, pp 327-332, issn 0090-4295, 6 p.Article

Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy. CommentaryGROSSFELD, Gary D; SMALL, Eric J; GROSSFELD et al.GROSSFELD et al.Urology (Ridgewood, NJ). 2001, Vol 58, Num 2A, pp 56-64, issn 0090-4295Conference Paper

Hypoxia-inducible factor-1α (HIF-1α) gene polymorphisms, circulating insulin-like growth factor binding protein (IGFBP)-3 levels and prostate cancerHAOJIE LI; BUBLEY, Glenn J; BALK, Stephen P et al.The Prostate. 2007, Vol 67, Num 12, pp 1354-1361, issn 0270-4137, 8 p.Article

Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer. CommentaryD'AMICO, Anthony; CARROLL, Peter R; BRUCE MALKOWICZ, S et al.Urology (Ridgewood, NJ). 2001, Vol 58, Num 2A, pp 78-82, issn 0090-4295Conference Paper

Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancerTAPLIN, Mary-Ellen; WANTING XIE; BUBLEY, Glenn J et al.Journal of clinical oncology. 2006, Vol 24, Num 34, pp 5408-5413, issn 0732-183X, 6 p.Article

An approach to heterobifunctional poly(ethyleneglycol) bioconjugatesLI, Jane; CRASTO, Curtis F; WEINBERG, James S et al.Bioorganic & medicinal chemistry letters (Print). 2005, Vol 15, Num 24, pp 5558-5561, issn 0960-894X, 4 p.Article